Neurocrine Biosciences, Inc.

NasdaqGS:NBIX Stock Report

Market Cap: US$14.0b

Neurocrine Biosciences Balance Sheet Health

Financial Health criteria checks 6/6

Neurocrine Biosciences has a total shareholder equity of $2.2B and total debt of $170.1M, which brings its debt-to-equity ratio to 7.6%. Its total assets and total liabilities are $3.3B and $1.0B respectively. Neurocrine Biosciences's EBIT is $394.8M making its interest coverage ratio -7.5. It has cash and short-term investments of $1.0B.

Key information

7.6%

Debt to equity ratio

US$170.10m

Debt

Interest coverage ratio-7.5x
CashUS$1.03b
EquityUS$2.23b
Total liabilitiesUS$1.02b
Total assetsUS$3.25b

Recent financial health updates

Recent updates

Neurocrine Biosciences Heads Into A Catalyst-Rich 2024 With Additional Upside

Feb 11

Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) Price In Tune With Earnings

Jan 07
Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) Price In Tune With Earnings

Neurocrine Biosciences (NASDAQ:NBIX) Could Easily Take On More Debt

Dec 11
Neurocrine Biosciences (NASDAQ:NBIX) Could Easily Take On More Debt

Does Neurocrine Biosciences (NASDAQ:NBIX) Have A Healthy Balance Sheet?

Sep 12
Does Neurocrine Biosciences (NASDAQ:NBIX) Have A Healthy Balance Sheet?

We Think Neurocrine Biosciences (NASDAQ:NBIX) Can Manage Its Debt With Ease

Jun 08
We Think Neurocrine Biosciences (NASDAQ:NBIX) Can Manage Its Debt With Ease

Neurocrine Biosciences (NASDAQ:NBIX) Has A Rock Solid Balance Sheet

Mar 08
Neurocrine Biosciences (NASDAQ:NBIX) Has A Rock Solid Balance Sheet

Does Neurocrine Biosciences (NASDAQ:NBIX) Have A Healthy Balance Sheet?

Dec 08
Does Neurocrine Biosciences (NASDAQ:NBIX) Have A Healthy Balance Sheet?

Neurocrine initiated Equal Weight at Wells Fargo despite upcoming catalysts

Sep 26

Neurocrine to acquire U.K.-based biotech Diurnal

Aug 30

Sosei to get $30M from Neurocrine as schizophrenia drug gets FDA nod to enter phase 2 trial

Aug 05

Neurocrine Biosciences (NASDAQ:NBIX) Seems To Use Debt Quite Sensibly

Jul 26
Neurocrine Biosciences (NASDAQ:NBIX) Seems To Use Debt Quite Sensibly

Better Ingrezza Sales And A Clinical Trial Read-Out Could Reignite Neurocrine Shares

Jul 19

Is Neurocrine Biosciences (NASDAQ:NBIX) A Risky Investment?

Apr 11
Is Neurocrine Biosciences (NASDAQ:NBIX) A Risky Investment?

Financial Position Analysis

Short Term Liabilities: NBIX's short term assets ($1.6B) exceed its short term liabilities ($654.8M).

Long Term Liabilities: NBIX's short term assets ($1.6B) exceed its long term liabilities ($364.6M).


Debt to Equity History and Analysis

Debt Level: NBIX has more cash than its total debt.

Reducing Debt: NBIX's debt to equity ratio has reduced from 80.8% to 7.6% over the past 5 years.

Debt Coverage: NBIX's debt is well covered by operating cash flow (229.2%).

Interest Coverage: NBIX earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Discover healthy companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.